AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update • Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau and a-syn • Cash resources of CHF 108.5 million as of ...

ACIU

<p>AC Immune 发布 2025 年第三季度财务报告并提供公司更新 • 加强对高价值资产的投资关注，包括三个处于第二阶段的活性免疫疗法项目和针对 NLRP3、Tau 和α-syn 的小分子项目 • 截至...现金资源为 1.085 亿瑞士法郎</p>

AC Immune 公布 2025 年第三季度财务业绩并提供公司最新动态